Did somebody say Galena also has a Superior pipeline of drug candidates that will blow the roof off the pps?
Sentiment: Strong Buy
The E75 vaccine (NeuVax) is the most studied of the HER2-derived peptide vaccines. The 9-amino-acid peptide E75 binds with major histocompatibility complex (MHC) class I molecules to stimulate CD8-positive T cells; when these T cells recognize a target as foreign, they attack it and release cytotoxic enzymes to kill it. Because E75 is an MHC class I peptide, the vaccine works only in patients whose cells are positive for human leukocyte antigen (HLA)-A2 or HLA-A3; only cells with those HLA types will present the peptide on the cell surface to activate T cells.
In May 2012, Elizabeth Mittendorf, M.D., Ph.D., an assistant professor in the Department of Surgical Oncology, and her colleagues published the 24-month landmark analysis of their phase I and II trials of E75. The group’s findings opened the door to the phase III PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study, currently the only phase III trial of a breast cancer vaccine. Dr. Mittendorf is the overall principal investigator of the multinational study.
This randomized, double-blind, placebo-controlled trial will enroll approximately 700 breast cancer patients who were rendered disease free following standard treatment. Patients must be positive for HLA-A2 or HLA-A3 and have had cancers that were scored as HER2 1+ or 2+ by immunohistochemistry. The vaccine will be given once a month for 6 months and then given as a booster inoculation every 6 months thereafter through 3 years. Because GM-CSF causes inflammation at the injection site, it will be given to patients in each study group, serving as the immunoadjuvant for the vaccine group and as an active placebo for the control group. The primary endpoint of the study is 3-year disease-free survival.
Positive results from this trial, researchers hope, would eventually lead to indications for the E75 vaccine in the routine care of breast cancer patients.
biopharm168, it would be interesting to know your handle before Jan. 19, 2015. I don't really care because you present pertinent info on Galena with credible references, but it would still be interesting to know why you initiated the new i.d.. Been here quite a spell, wife had BC Her2+ all the treatments + herceptin, 4 years now doing fine. Would Neuvax (were it to become available be a treatment option?) BC is tough, science making progress, hopefully Neuvax will provide additional hope for all.
to anyone who has been following Nektar for awhile (former employee of nektar)?
He was just hired over at Galena.....just wondering if he had his marbles lined up.
Do you believe it is the " Dr. Constantine Loannides" who is posting on this board? I have my doubt's.
Long gale for several years and holding for a major break-thru.
A couple of weeks does not make a year. Turbulent times, $$ to be made or lost. Largest casino in the world and we are in the middle of it. Galena will win this contest running away 100% DFS when combo with herceptin....hard to believe but time will tell.